menu
    • menu

    Company profile for Nanjing Well Pharmaceutical

    Nanjing Well Pharmaceutical-PSE
    News
    Nanjing Weier Pharma: Environmental Monitoring Q1 2026

    20 May 2026

    // PRESS RELEASE

    Nanjing Well Biotech: Self-Monitoring Plan & Report Mar 2026

    07 May 2026

    // PRESS RELEASE

    Nanjing Well Biotech: Self-Monitoring Plan & Report Feb 2026

    06 May 2026

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Nanjing Well Pharmaceutical RM

    Contact Supplier

    Website

    CPhI China

    Booth #E3D78A

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/top-pharma-companies-drugs-in-2025-lilly-vaults-eight-spots-to-emerge-at-the-top-glp-1-drugs-dominate-list

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    EXCIPIENTS

    Key Products KEY EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    PharmaCompass

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Related CompaniesRelated Companies

    About

    Nanjing Well Pharmaceutical Group was established in 2000 & is committed to R&D & manufacture of pharmaceutical materials, base oils of advanced synthetic lubricants, etc. The group has 10 subsidiaries, which are distributed in Nanjing, Yangzhou, & other cities in China. Nanjing Well Pharmaceutical Technology is a wholly-owned subsidiary of the Group, & it is a new R&D & manufacturing center for pharmaceutical excipients & APIs. It is located in Nanjing Jiangbei New Material Science & Technology Park with 200+ employees & has 15 synthetic production lines which can achieve an annual output of >20,000 tons of pharmaceutical excipients & APIs.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nanjing Well PharmaceuticalChina Flag
    Country
    Country
    China
    Address
    Address
    No.99, Changfenghe West Road, Chemical industrial Park, Nanjing, 210047
    Telephone
    Telephone
    +86 02583172922
    Client Email
    Email
    missliang999@outlook.com
    Client Website
    Website
    http://www.wellnj.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    lmq@wellnj.com

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI China

    Booth #E3D78A

    envelop Contact Supplier

    CPhI China

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/nanjing-well-pharmaceutical-party-content-89758.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/nanjing-well-pharmaceutical-party-content-90930.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    MPLA & QS-21

    read-more

      https://www.pharmacompass.com/pdf/party/content/nanjing-well-pharmaceutical-party-content-12228.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    PharmaCompass is introducing a new regulatory update that tracks developments in Certificates of Suitability to the Monographs of the European Pharmacopoeia, referred to as CEPs. These certificates are a critical regulatory instrument in the global pharmaceutical supply chain.Also known as a Certification of Suitability (COS), CEPs are issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM), with or without inspection of the manufacturing site. A CEP must be renewed every five years from its original issue date to remain valid, regardless of any revisions made during the interim period. However, a CEP does not replace Good Manufacturing Practice certification.CEPs are recognized as a trusted reference for API quality, thereby simplifying global registration strategies. Apart from Europe, the CEP system is widely used by many regulatory authorities, including those in Canada, Australia, Brazil, Singapore and South Africa. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)CEP 2.0 enhances regulatory clarity, brings efficiency, global interoperability There are several types of CEPs, depending on the nature of the substance and evaluation. The most common type is the Chemical CEP, which confirms that a chemically synthesized API meets standards for purity and impurity control. Then there are Herbal CEPs for herbal substances and preparations.Another key category is the TSE CEP, which addresses risks associated with transmissible spongiform encephalopathies in animal-derived materials. In addition, there are Combined CEPs that may cover multiple aspects, such as chemical quality, TSE risk, and sterility. However, biological products such as vaccines and blood products fall outside the scope of the CEP framework.In 2023, the CEP system underwent a major transformation with the introduction of CEP 2.0, which marks a shift from a largely document-based system to a more structured, transparent, and digitally aligned model. This makes it easier for companies to manage compliance while improving trust among global regulators.While increasing data and compliance requirements for API manufacturers, CEP 2.0 enables better regulatory clarity, streamlined dossier integration, and stronger global acceptance. Overall, CEP 2.0 is designed to enhance regulatory clarity while making the system more efficient and globally interoperable. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Indian firms issued maximum CEPs; Sun Pharma and its subsidiaries, Jubilant Biosys top listIndia topped the charts for CEPs issued, both in terms of new CEPs and revisions in the first quarter (Q1) of 2026. Indian companies were issued 81 new CEPs in Q1 2026 (as against 40 in Q1 2025) and 203 revisions (as against 129 in Q1 2025). In comparison, Chinese companies were issued 42 new CEPs in Q1 2026 (against 25 in Q1 2025) and 53 revisions (against 67 in Q1 2025). Italy came a distant third, followed by Germany and Spain.India’s Sun Pharmaceuticals and its subsidiaries topped the list of companies with the maximum number of CEPs issued— while no new CEP was issued, 27 CEPs were revised in Q1 2026. At second place was Jubilant Biosys — 21 CEPs were revised in Q1 2026.In terms of products, the maximum CEPs were issued for amlodipine besylate (a calcium channel blocker used for treating hypertension), followed by sitagliptin phosphate (a type 2 diabetes medicine) and pregabalin (a drug used to treat neuropathic pain, fibromyalgia, seizures, and generalized anxiety disorder). Both amlodipine besylate and sitagliptin phosphate had not been issued new CEPs or revisions in Q1 2025. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)EDQM introduces new guidelines to accelerate CEP assessments The EDQM charges fees for various services related to CEPs that depend on the type of request or regulatory activity involved. In general, fees apply to handling CEP applications, revisions or renewals and for offering technical advice (where applicants seek scientific or regulatory guidance).In March 2026, the EDQM introduced two new guidelines aimed at accelerating CEP assessments. The first is a reliance-based assessment pathway, which allows regulators to leverage prior approvals from trusted authorities, such as those in the EU, UK, Australia, Canada, and the WHO pre-qualification program. The second is a fast-track assessment route designed to expedite reviews in situations such as medicine shortages and to support initiatives like the EU Critical Medicines Act.Timelines have been significantly compressed under these new pathways. Initial evaluations are completed within 46 working days, compared to up to 115 days under the standard procedure. Applicants are given 30 calendar days to respond to queries, after which regulators complete the final assessment within 23 working days.Another important regulatory update relates to electronic submissions. From April 1, 2026, the EDQM will reject non-compliant CEP applications at the point of submission. All applications must include a validated electronic Common Technical Document (eCTD) dossier along with a proper validation report, submitted in line with the updated Common European Submission Portal (CESP) guidelines. Taken together, these developments signal a more rigorous yet efficient CEP ecosystem. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Our viewThe shift to CEP 2.0 signals a move toward greater transparency, digitalization, and global regulatory alignment. Though enhanced disclosure and stricter e-submission requirements may increase the compliance burden, especially for smaller manufacturers, the long-term gains are expected to be significant. Going forward, companies that invest in data quality and regulatory readiness stand to gain from these changes.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2693

    https://www.pharmacompass.com/radio-compass-blog/cep-q1-2026-update-cep-2-0-edqm-s-new-guidelines-strengthen-ecosystem-indian-firms-top-list-of-ceps-issued

    #PharmaFlow by PHARMACOMPASS
    09 Apr 2026
    Share Share
    Excipient Market Overview: Clariant sets up its first PEG excipients facility in US; India harmonizes 22 excipient monographs

    Excipient Market Overview: Clariant sets up its first PEG excipients facility in US; India harmonizes 22 excipient monographs

    The market for pharmaceutical excipients — or inactive substances used in the production of drugs —  continued to witness significant transformation in the first quarter (Q1) of 2026. The rise of biologics, increasing demand for personalized medicine, and innovations in drug delivery systems are driving demand for a wider range of functional excipients. As a result, the pharmaceutical excipients market is estimated to grow at a compound annual growth rate (CAGR) of 5.75 percent, to exceed US$ 15.43 billion by 2034. Its size was estimated at US$ 9.31 billion in 2025. The North American market for excipients was estimated at US$ 3.1 billion in 2024 and is estimated to increase to US$ 5.66 billion by 2034. In comparison, the European market for pharmaceutical excipients was estimated at US$ 2.35 billion in 2024 and is predicted to reach around US$ 3.95 billion by 2034, while the Asia Pacific market stood at US$ 1.94 billion in 2024 and is projected to grow to US$ 3.65 billion by 2034.The sector remains highly competitive and fragmented. Major excipient providers include BASF, Roquette, Gangwal Healthcare, Croda International, DuPont, Seqens, SPI Pharma, Evonik, PMC Isochem, Pfanstiehl, Colorcon, Kewpie Corporation, ICE Pharma, Nanjing Well Pharmaceutical, Merck KGaA-owned MilliporeSigma, Minakem, Ashland Global and Nippon Fine Chemical.Clariant sets up its first PEG excipients facility in US; Croda opens greenfield facility in India Swiss specialty chemical company Clariant is expanding its Clear Lake (Texas) site to include GMP-compliant manufacturing of pharmaceutical-grade polyethylene glycol (PEG) excipients. This will improve availability and reliability for North American customers, with extended reach to Latin America. The multi-phase expansion addresses critical industry priorities around supply chain security, continuity, and responsiveness while demonstrating Clariant’s long-term strategic commitment to the US pharmaceutical market. This is the first Clariant facility in the US to manufacture PEG excipients for oral and topical applications.British specialty chemicals company Croda International has inaugurated a greenfield manufacturing facility in Dahej, India, that strengthens its ability to serve fast-growing markets in Asia. The new site represents a significant investment in India and will enhance Croda’s supply capabilities, improve responsiveness to customer demand, and support future growth in high-value sectors. Located in Gujarat, the facility benefits from strong logistics connectivity and is designed to serve both domestic customers and select export markets. It will support demand across Croda’s consumer care, life sciences, and industrial specialties sectors. Following the acquisition of IFF Pharma Solutions in 2025, French excipient company Roquette has introduced an expanded cosmetics portfolio under the Roquette Beauté brand. This portfolio integrates IFF Pharma Solutions’ ingredients — Methocel, Avicel, Aquacoat, Ethocel, and Polyox — with Roquette’s legacy range, while its core portfolio continues to include widely used pharmaceutical excipients. View Our Dashboard on Major Excipient Companies in 2026 (Free Excel Available)SPI Pharma-Anek Prayog, Ingredion-Univar ink distribution deals; DFE Pharma, Gericke launch CM platformIn February, US-based pharmaceutical excipient and ingredients company SPI Pharma announced a global distribution partnership with Indian pharmaceutical excipient manufacturer Anek Prayog. Under this agreement, SPI will exclusively sell, promote, and distribute Lubripharm Pro SSF, a next-generation sodium stearyl fumarate lubricant manufactured by Anek Prayog.The Ingredients + Specialties division of Univar Solutions was appointed as a distributor for Ingredion Pharma Solutions. The agreement includes distribution of Ingredion’s global pharmaceuticals portfolio and positions Univar as the exclusive distributor of pharmaceutical starches in the US and Canada. The partnership expands its pharmaceutical and nutraceutical excipient offerings, including binders, fillers, superdisintegrants, lubricants, and gelatin alternatives.German excipient solutions company DFE Pharma has launched a continuous manufacturing (CM) platform in collaboration with Switzerland-based Gericke Group to support formulation development, optimization, and lifecycle management. The platform integrates CM-ready excipients, a flexible evaluation environment, and multidisciplinary expertise to enable data-driven decisions from early development to commercial manufacturing.As part of this initiative, DFE Pharma has established CM capabilities at its C2F Center of Excellence in Hyderabad, featuring a Gericke Formulation Skid (GFS) in a non-GMP setup. This modular system enables rapid testing, process optimization, and practical assessment of continuous feeding and blending without impacting existing GMP operations, while supporting alignment with ICH Q13 (an international guideline on CM for drug substances and products).Gangwal Healthcare operates EXCiPACT-certified GMP facilities and offers a broad range of functional excipients, including co-processed blends like ProBlend, Starlose, Tyloxapole, and Microlose. Its excipients, including Solvostar (sodium starch glycolate) and LubMag-W (Magnesium Stearate, Sodium Lauryl Sulfate), support enhanced tablet disintegration and drug release. The company also provides taste-masking agents such as SucreX (sucralose) and CutCal (neotame), supporting the development of patient-friendly oral dosage forms. View Our Dashboard on Major Excipient Companies in 2026 (Free Excel Available)India harmonizes 22 excipient monographs; EMA updates TE guidelines for inhalation products Regulators are increasingly tightening requirements around excipients, as they are no longer treated as passive ingredients. They are being recognized as critical to product performance and therapeutic equivalence.India has introduced the Indian Pharmacopoeia 2026 with updated and harmonized standards for pharmaceutical ingredients, including 22 excipient monographs. These revisions align Indian standards more closely with global pharmacopoeias. For excipient manufacturers and drug formulators, this means stricter compliance expectations. In August, India had notified an amendment to the Drugs Rules, 1945 to mandate inclusion of qualitative details of excipients in drug labels through barcodes or QR codes from 2026.The European Medicines Agency (EMA) has issued updated guidelines on the pharmaceutical quality of inhalation and nasal medicines, as well as on demonstrating therapeutic equivalence (TE) of orally inhaled products (OIP) for asthma and chronic obstructive pulmonary disease. These guidelines require manufacturers to provide detailed information on the active substance, finished product composition, pharmaceutical development studies, and the control of excipients and other formulation components. Similar pharmaceutical quality requirements apply to nasal products under the pharmaceutical quality guideline.Excipients are becoming increasingly linked to manufacturing technologies. For instance, the US Food and Drug Administration (FDA) finalized its Advanced Manufacturing Technologies (AMT) Designation Program in 2024. This is expected to increase the need for excipients compatible with such technologies. View Our Dashboard on Major Excipient Companies in 2026 (Free Excel Available)Our view While the market for excipients is growing at a healthy pace, the ongoing conflict in the Middle East is disrupting pharmaceutical supply chains, with impacts now extending beyond APIs to critical excipients and packaging materials. Surging crude oil prices are driving up the cost of excipients, with key inputs like chloroform witnessing sharp price increases. In addition, disruptions in logistics are forcing drugmakers to reroute shipments through longer and more expensive routes due to closure of airports and certain sea routes. These developments will have a cascading effect on the pharmaceutical industry and its supply chain in the coming months.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2670

    https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-clariant-sets-up-its-first-peg-excipients-facility-in-us-india-harmonizes-22-excipient-monographs

    #PharmaFlow by PHARMACOMPASS
    26 Mar 2026
    Share Share
    Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

    Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

    The global pharmaceutical excipients market continued to evolve in the third quarter (Q3) of 2025, supported by rising demand for functional excipients, growth in production of generics, and advances in drug delivery technologies. The global market for pharmaceutical excipients was estimated at US$ 9.8 billion to US$ 10.7 billion in 2024, and is projected to grow at a compound annual growth rate (CAGR) of 4.1 to 6.6 percent through 2030. At this pace, the market is expected to reach US$ 13.05 billion to US$ 14.86 billion by 2030. Europe retained the largest market share in 2024, followed by Asia-Pacific. Key drivers shaping the excipients market include the rising prevalence of chronic diseases, expansion of biologics and biosimilars, and increasing quality and regulatory expectations. Increased investments in facility expansions and ongoing reforms in clinical trial regulations are also facilitating market growth. The sector remains highly competitive and fragmented. Major excipient providers include BASF, Roquette, Gangwal Healthcare, DuPont, Evonik, Seqens, SPI Pharma, PMC Isochem, Croda International, Pfanstiehl, Colorcon, Kewpie Corporation, ICE Pharma, Nanjing Well Pharmaceutical, Merck KGaA owned MilliporeSigma, Minakem, Ashland Global, Actylis and Nippon Fine Chemical.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)  Evonik in partnership with Ethris; Colorcon Ventures invests in Phytolon   The market saw strategic collaborations across the excipients and drug formulation ecosystem in Q3 2025. Evonik entered into a partnership with Ethris to strengthen its nucleic acid delivery platform. The collaboration integrates Ethris’ proprietary technology — its lipidoid nanoparticle platform, known as SNaP LNP — into Evonik’s CDMO offerings, enhancing the latter’s ability to support RNA-based therapeutics from concept to clinic. Colorcon Ventures, the investment arm of Colorcon, announced a strategic investment in Israel-based Phytolon. The biotechnology start-up uses precision fermentation to develop natural colorants. The investment underscores Colorcon’s commitment to next-generation coloring technologies that support cleaner-label formulations and innovation in oral solid dosage coatings.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   Evonik launches MaxiPure Polysorbate 80; Asahi Kasei expands its portfolio The quarter saw continued innovation in high-purity and injectable-grade excipients. Evonik introduced MaxiPure Polysorbate 80, a high-purity injectable-grade surfactant designed for biologics and parenteral formulations. This excipient addresses key challenges such as protein stability, viral inactivation, and the solubilization of hydrophobic APIs, while meeting regulatory expectations across global markets. Asahi Kasei expanded its Sonanos portfolio of excipients with two new products — Sonanos PG (optimized for sustained release of biologics and peptides while supporting patient-friendly dosing)  and Sonanos DS (developed to enhance solubility of poorly water-soluble APIs). These additions reflect growing industry demand for dosage optimization, stability, and specialized delivery of complex molecules. Gangwal Healthcare operates EXCiPACT-certified GMP facilities and offers a broad range of functional excipients, including co-processed blends like ProBlend, Starlose, and Microlose. Its excipients, including Solvostar (sodium starch glycolate) and Sallyso (croscarmellose sodium), support enhanced tablet disintegration and drug release. The company also provides taste-masking agents such as SucreX (sucralose) and CutCal (neotame), supporting the development of patient-friendly oral dosage forms.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   Colorcon, Gattefossé, Croda, Roquette, Clariant expand manufacturing capacities Manufacturing investments and facility expansions remained a key trend during Q3 2025. Colorcon inaugurated a new state-of-the-art, film coating manufacturing facility in Johor, Malaysia. The site incorporates energy-efficient systems and advanced production technologies to strengthen Colorcon’s functional-excipient supply network across Asia. Gattefossé opened a new lipid-based excipient facility in Texas (US), marking a strategic expansion of its North American manufacturing footprint. Croda International expanded its Leek, UK facility with a lipid system synthesis unit and enhanced R&D capabilities. The site will support the launch of Super Refined Poloxamer 188, a highly purified fast-dissolving granular excipient. Roquette announced the opening of a dedicated innovation center in São Paulo, Brazil, strengthening its engagement with regional drug developers. Clariant expanded its Daya Bay, China facility, adding a second spray tower dedicated to pharmaceutical excipient production. The upgraded site increases capacity for excipients used in laxatives and other formulations. BASF also strengthened its commitment to biopharma and pharmaceutical ingredients with a new GMP Solution Center in Michigan (US). The facility expands BASF’s network of poloxamer (a synthetic polymer) manufacturing sites. With state-of-the-art clean room packaging and high-sensitivity analytical testing, this new facility will enable close collaboration with BASF’s customers on customized chemistries for product development.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   India mandates excipient disclosure; new rules to apply from March 2026  India has made it mandatory to disclose excipient details from March 2026 under the country’s new Drugs (2nd Amendment) Rules, 2025. This applies to Schedule H2 medicines. The final notification expands earlier draft requirements by mandating qualitative excipient details in QR codes on product packaging. This should enhance transparency and support patient safety. Meanwhile, US pharmaceutical groups have responded to the US Food and Drug Administration’s draft guidance proposing simplified pathways for replacing color additives in drug products. Industry associations have supported draft guidance, noting that it reduces regulatory burden while maintaining product quality and consistency.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   Our view While the fast-growing generics market is creating demand for cost-effective and versatile excipients, the market is also witnessing innovations tailored to the specialized needs of biologics and biosimilars. India is poised to become a key player in the global excipient market, supported by the rapid growth in its generic drug industry, expansion of its health infrastructure and increasing investments in R&D. The new excipient-disclosure rules, therefore, are likely to benefit the global excipient industry by improving transparency and strengthening quality ecosystems.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 6767

    https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-evonik-launches-high-purity-excipients-india-mandates-disclosures-from-march-2026

    #PharmaFlow by PHARMACOMPASS
    20 Nov 2025
    Share Share
    Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

    Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

    The pharmaceutical excipients market saw significant strategic consolidations, technological developments, and regulatory adaptations in 2025. Globally, the pharmaceutical excipients sector is growing at a compound annual growth rate of 6.6 percent, and was valued at US$ 8.85 billion in 2024. It is projected to reach US$ 14.77 billion by 2032.This year, the sector is witnessing technological advancements, regulatory evolution, and strategic business realignments. North America continues to dominate the global excipients landscape, with a 39.8 percent market share. The Asia-Pacific region is the fastest-growing segment with a substantial 30.4 percent market share, driven by increasing investments in pharmaceutical manufacturing, growing demand for cost-effective drugs, and rising healthcare expenditure across developing economies.Major excipient providers include BASF, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, DuPont, Evonik, Seqens, Actylis, SPI Pharma, PMC Isochem, Croda International, Pfanstiehl, Kewpie Corporation, Boai NKY Pharmaceuticals, ICE Pharma, Roquette, Nanjing Well Pharmaceutical, Minakem, Ashland Global, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Roquette restructures after buying IFF Pharma; Colorcon partners ASHA CelluloseIn May, Roquette completed its acquisition of IFF Pharma Solutions. Valued at up to US$ 2.85 billion in enterprise value, this transaction represents a major consolidation in the pharmaceutical excipients market. The acquisition significantly enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide. Roquette announced a comprehensive, new organizational structure following the acquisition, indicating the company’s commitment to integrate IFF Pharma Solutions’ capabilities seamlessly into its existing operations. This consolidation creates a more robust platform for addressing the growing demand for specialized excipients in complex drug formulations, particularly as the industry moves towards more personalized approaches to medicines.So far, the year has also witnessed some strategic alliances, such as Colorcon’s partnership with ASHA Cellulose. As part of the deal, Colorcon will become the exclusive representative for two ASHA products — ASHACEL and ASHAKOTE — throughout Europe, the Middle East, Africa, Northeast Asia and Southeast Asia.Brenntag Specialties has announced an exclusive distribution agreement with MEGGLE Excipients to expand market reach. This collaboration makes available a broad portfolio of over 30 high-quality lactose-based excipients for various applications in the pharmaceutical industries across the Netherlands, Belgium, Norway, Finland, and Sweden.The portfolio’s versatility offers optimal solutions for a wide range of pharmaceutical applications, including tableting through both granulation and direct compression, powder preparations, and dry powder inhalation. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)WHO, FDA drive new standards with GMP guidelines; Pfanstiehl launches injectable-grade glycineIn March, the World Health Organization had put out a publication titled “Good Manufacturing Practices for Excipients used in Pharmaceutical Products.” WHO’s excipient GMP guideline emphasizes modern quality management principles, comprehensive risk assessment protocols, and supplier qualification procedures for excipients across all stages of production, storage, and distribution.Meanwhile, the US Food and Drug Administration (FDA) has proposed amendments to the Food, Drug, and Cosmetic Act as part of its FY 2025 legislative proposals, specifically targeting supply chain transparency for high-risk excipients. The FDA proposal would require certain excipients designated as high-risk to carry labeling that identifies the original manufacturer’s name and address. This initiative addresses what FDA has identified as a lack of transparency in excipient supply chains.In April, IFF Pharma Solutions launched Low Nitrite METHOCEL hydroxypropyl methylcellulose (HPMC). This innovative product is specifically designed to reduce the risk of nitrosamine formation in finished pharmaceutical dosages, addressing one of the most pressing concerns in contemporary pharmaceutical manufacturing.Pfanstiehl, a global leader in high-purity excipient manufacturing, announced the launch of its High Purity Low Endotoxin Low Metals (HPLE-LM) injectable-grade glycine. This multi-compendial glycine is specifically engineered for use in biologics, vaccines, and the downstream purification of monoclonal antibodies (mAbs). Manufactured under ICH-Q7 cGMP regulations at Pfanstiehl’s advanced facility in Waukegan, Illinois, the product meets stringent global pharmacopeial standards. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Shin-Etsu Chemical invests in Japan, Germany to expand cellulose productionIn March, Shin-Etsu Chemical announced investments in pharmaceutical cellulose business operations in Japan and Europe, thereby showing significant commitment to market expansion. The company is making substantial investments at two key bases: the subsidiary SE Tylose GmbH in Germany, and the Naoetsu Plant in Joetsu, Japan. In Germany, a new production facility for the pharmaceutical excipient L-HPC will be built adjacent to the existing facility, creating a dual base with the Naoetsu Plant. The excipients market in 2025 has seen innovation in functional applications. Research on BENEO’s Palatinose as a bedtime drink shows that it improves aspects of sleep and represents an innovative approach to excipient functionality. Palatinose is a naturally sourced, smart carbohydrate that provides full carbohydrate energy in a more balanced way, thanks to its low-glycemic profile.Gangwal Healthcare, with its EXCiPACT-certified GMP facilities and a robust portfolio of co-processed excipients like ProBlend, Starlose, and Microlose, is actively contributing to the pharmaceutical industry’s demand for functional excipients. The company also offers cellulose-based excipients such as Solvostar (Sodium Starch Glycolate) and Sallyso (Croscarmellose Sodium), designed to improve tablet disintegration and drug release profiles in oral solid dosage forms.Evonik announced a partnership with South Korea–based CDMO ST Pharm to expand its RNA and nucleic acid delivery services. This collaboration enables Evonik to integrate customized nucleic acids from ST Pharm seamlessly with its lipid and lipid nanoparticle (LNP) development and fill-and-finish services. This streamlined approach means that pharmaceutical companies can reduce complexity and increase speed-to-market for nucleic acid therapeutics. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Our viewThe pharmaceutical excipients market in 2025 is being shaped by several key trends including the development of multifunctional excipients that can simultaneously improve solubility, bioavailability, and control drug release in increasingly complex formulations.Moreover, the expanding generic medicines market is creating demand for cost-effective, versatile excipients. The growing importance of biologics and biosimilars is driving innovation in specialized excipients designed to maintain the stability and efficacy of these complex therapeutic products throughout their lifecycle. And nanotechnology continues to enable advanced nano-excipients for enhanced drug delivery and efficacy.In addition to these trends, we also notice a shift towards natural and plant-based excipients that is driven by sustainability concerns and potential biocompatibility benefits. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 5812

    https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks

    #PharmaFlow by PHARMACOMPASS
    29 May 2025
    Share Share
    Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination

    Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination

    The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards.  Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio.  Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients.  The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.   
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4300

    https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-seqens-evonik-make-strategic-moves-new-guidelines-deal-with-contamination

    #PharmaFlow by PHARMACOMPASS
    12 Sep 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Nanjing Weier Pharma: Environmental Monitoring Q1 2026
    Nanjing Weier Pharma: Environmental Monitoring Q1 2026

    20 May 2026

    // PRESS RELEASE

    http://www.wellnj.com/cms/gongsidongtai/439.html

    PRESS RELEASE
    20 May 2026
    Share Share
    Nanjing Well Biotech: Self-Monitoring Plan & Report Mar 2026
    Nanjing Well Biotech: Self-Monitoring Plan & Report Mar 2026

    07 May 2026

    // PRESS RELEASE

    http://www.wellnj.com/cms/gongsidongtai/438.html

    PRESS RELEASE
    07 May 2026
    Share Share
    Nanjing Well Biotech: Self-Monitoring Plan & Report Feb 2026
    Nanjing Well Biotech: Self-Monitoring Plan & Report Feb 2026

    06 May 2026

    // PRESS RELEASE

    http://www.wellnj.com/cms/gongsidongtai/437.html

    PRESS RELEASE
    06 May 2026
    Share Share
    Nanjing Weier Pharma: Hazardous Waste Disclosure Q1 2026
    Nanjing Weier Pharma: Hazardous Waste Disclosure Q1 2026

    13 Apr 2026

    // PRESS RELEASE

    http://www.wellnj.com/cms/gongsidongtai/436.html

    PRESS RELEASE
    13 Apr 2026
    Share Share
    Nanjing Well Biotech: Self-Monitoring Plan & Report Jan 2026
    Nanjing Well Biotech: Self-Monitoring Plan & Report Jan 2026

    14 Feb 2026

    // PRESS RELEASE

    http://www.wellnj.com/cms/gongsidongtai/434.html

    PRESS RELEASE
    14 Feb 2026
    Share Share
    Nanjing Well Biotech: Self-Monitoring Plan & Report Dec 2025
    Nanjing Well Biotech: Self-Monitoring Plan & Report Dec 2025

    14 Feb 2026

    // PRESS RELEASE

    http://www.wellnj.com/cms/gongsidongtai/433.html

    PRESS RELEASE
    14 Feb 2026
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    2-Dodecoxyethanol

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Nanjing Well Pharmaceutical

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Macrogol

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Nanjing Well Pharmaceutical

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Mono Propylene Glycol

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Nanjing Well Pharmaceutical

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Polidocanol

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Nanjing Well Pharmaceutical

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Discover the DDS // excipients from this company

    KEY EXCIPIENTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Nanjing Well Pharmaceutical full-view
    Egg Yolk Lecithin
    full-view
    Benzyl Alcohol
    full-view
    Benzyl Alcohol
    full-view

    Excipients by Ingredients

    Discover their expertise by components

    Excipients By applications

    Discover their expertise by claims

    Parenteral

    read-more
    read-more

    01

    Brand Name : 2-Amino-2-Methyl-1-Propan...

    China
    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Dosage Form : Ophthalmic Solution

    Grade : Parenteral

    Nanjing Well Pharmaceutical

    Application : Parenteral

    Excipient Details : 2-Amino-2-methyl-1-propanol is used as a viscosity-enhancing agent and lubricant in ophthalmic formulations.

    Pharmacopoeia Ref : NA

    Technical Specs : NA

    Ingredient(s) : 2-Amino-2-methyl-1-propanol Excipient

    arrow
    2-Amino-2-Methyl-1-Propanol
    CPhI China
    Booth #E3D78A

    Excipients Web Link

    Market Place

    02

    Brand Name : Benzyl Alcohol

    China
    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Dosage Form : Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Tablet

    Grade : Parenteral, Oral, Topical

    Nanjing Well Pharmaceutical

    Application : Parenteral, Solubilizers, Topical

    Excipient Details : Benzyl alcohol is used as a bacteriostatic & preservative in parenteral & ophthalmic products. It is widely used in oral & topical formulations.

    Pharmacopoeia Ref : ChP/USP/EP/JP

    Technical Specs : NA

    Ingredient(s) : Benzyl Alcohol

    arrow
    Nanjing Well Benzyl Alcohol
    CPhI China
    Booth #E3D78A

    Excipients Web Link

    Market Place

    03

    Brand Name : Castor Oil

    China
    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Dosage Form : Injectable / Parenteral

    Grade : Parenteral

    Nanjing Well Pharmaceutical

    Application : Parenteral

    Excipient Details : Castor oil is used as an oily solvent in parenteral dosage forms.

    Pharmacopoeia Ref : USP/EP/JP

    Technical Specs : NA

    Ingredient(s) : Castor Oil Excipient

    arrow
    Nanjing Well Castor Oil
    CPhI China
    Booth #E3D78A

    Excipients Web Link

    Market Place

    04

    Brand Name : Cholesterol

    China
    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Dosage Form : Injectable / Parenteral, Solution

    Grade : Parenteral

    Nanjing Well Pharmaceutical

    Application : Controlled & Modified Release, Parenteral

    Excipient Details : Cholesterol is used as a sustained release material for drug delivery systems in injectable formulations.

    Pharmacopoeia Ref : ChP/USP/EP/JP

    Technical Specs : NA

    Ingredient(s) : Cholesterol Excipient

    arrow
    Cholesterol
    CPhI China
    Booth #E3D78A

    Excipients Web Link

    Market Place

    05

    Brand Name : Dierucoyl Phosphatidychol...

    China
    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Dosage Form : Injectable / Parenteral, Solution

    Grade : Parenteral

    Nanjing Well Pharmaceutical

    Application : Controlled & Modified Release, Parenteral

    Excipient Details : Dierucoyl phosphatidylcholine is used as a sustained release material for drug delivery systems in injectable formulations.

    Pharmacopoeia Ref : NA

    Technical Specs : NA

    Ingredient(s) : DEPC Excipient

    arrow
    Dierucoyl Phosphatidycholine
    CPhI China
    Booth #E3D78A

    Excipients Web Link

    Market Place

    06

    Brand Name : Dimethyl Dioctadecyl Ammo...

    China
    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Dosage Form : Injectable / Parenteral

    Grade : Parenteral

    Nanjing Well Pharmaceutical

    Application : Parenteral

    Excipient Details : Dimethyl dioctadecyl ammonium bromide (DDAB) is used as vaccine adjuvants CAF01.

    Pharmacopoeia Ref : NA

    Technical Specs : NA

    Ingredient(s) : Dimethyl Dioctadecyl Ammonium Bromide (DDAB)

    arrow
    Dimethyl Dioctadecyl Ammonium Bromide
    CPhI China
    Booth #E3D78A

    Excipients Web Link

    Market Place

    07

    Brand Name : Dioleoyl Phosphatidylchol...

    China
    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Dosage Form : Injectable / Parenteral, Solution

    Grade : Parenteral

    Nanjing Well Pharmaceutical

    Application : Controlled & Modified Release, Parenteral

    Excipient Details : Dioleoyl phosphatidylcholine is used as a sustained release material for drug delivery systems in injectable formulations.

    Pharmacopoeia Ref : NA

    Technical Specs : NA

    Ingredient(s) : Dioleoyl Phosphatidylcholine Excipient

    arrow
    Dioleoyl Phosphatidylcholine
    CPhI China
    Booth #E3D78A

    Excipients Web Link

    Market Place

    08

    Brand Name : Dioleoyl Phosphatidylglyc...

    China
    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Dosage Form : Injectable / Parenteral, Solution

    Grade : Parenteral

    Nanjing Well Pharmaceutical

    Application : Controlled & Modified Release, Parenteral

    Excipient Details : Dioleoyl phosphatidylglycerol sodium salt is used as a sustained release material for drug delivery systems in injectable formulations.

    Pharmacopoeia Ref : NA

    Technical Specs : NA

    Ingredient(s) : DOPG Excipient

    arrow
    Dioleoyl Phosphatidylglycerol Sodium
    CPhI China
    Booth #E3D78A

    Excipients Web Link

    Market Place

    09

    Brand Name : Dipalmitoyl Phosphatidylc...

    China
    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Dosage Form : Injectable / Parenteral, Solution

    Grade : Parenteral

    Nanjing Well Pharmaceutical

    Application : Controlled & Modified Release, Parenteral

    Excipient Details : Dipalmitoyl phosphatidylcholine is used as a sustained release material for drug delivery systems in injectable formulations.

    Pharmacopoeia Ref : NA

    Technical Specs : NA

    Ingredient(s) : Phospholipid DMPC

    arrow
    Dipalmitoyl Phosphatidylcholine
    CPhI China
    Booth #E3D78A

    Excipients Web Link

    Market Place

    10

    Brand Name : Dipalmitoyl Phosphatidylg...

    China
    arrow
    CPhI China
    Booth #E3D78A
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Dosage Form : Injectable / Parenteral, Solution

    Grade : Parenteral

    Nanjing Well Pharmaceutical

    Application : Controlled & Modified Release, Parenteral

    Excipient Details : Dipalmitoyl phosphatidylglycerole sodium salt is used as a sustained release material for drug delivery systems in injectable formulations.

    Pharmacopoeia Ref : NA

    Technical Specs : NA

    Ingredient(s) : Dipalmitoyl Phosphatidylglycerole Sodium Salt

    arrow
    Dipalmitoyl Phosphatidylglycerole Sodium
    CPhI China
    Booth #E3D78A

    Excipients Web Link

    Market Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Contact Nanjing Well Pharmaceutical and get a quotation

    Nanjing Well Pharmaceutical is a supplier offers 4 products (APIs, Excipients or Intermediates).

    Find 2-Dodecoxyethanol bulk offered by Nanjing Well Pharmaceutical

    Find Macrogol bulk offered by Nanjing Well Pharmaceutical

    Find Mono Propylene Glycol bulk offered by Nanjing Well Pharmaceutical

    Find Polidocanol bulk offered by Nanjing Well Pharmaceutical

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search